NCT07262970 2025-12-04Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a TumorRezoluteAvailable
NCT03583528 2025-06-13DOTATOC PET/CT for Imaging NET PatientsBritish Columbia Cancer AgencyActive not recruiting800 enrolled
NCT00427349 2023-07-05AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine TumorsEastern Cooperative Oncology GroupPhase 2 Completed46 enrolled 7 charts
NCT00227617 2023-05-22Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine TumorsUniversity of California, San FranciscoPhase 2/3 Terminated36 enrolled 14 charts
NCT04915144 2023-02-21177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETsBritish Columbia Cancer AgencyPhase 2 Withdrawn
NCT02831179 2017-09-28Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorVanderbilt-Ingram Cancer CenterPhase 1 Withdrawn